Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, non-prostate

2534 - Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible


09 Oct 2016


Genitourinary tumours, non-prostate


Manish Patel


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


M.R. Patel1, J. Ellerton2, M. Agrawal3, M. Gordon4, L. Dirix5, K. Lee6, J. Infante7, M. Schlichting8, K. Chin9, A.B. Apolo10

Author affiliations

  • 1 Sarah Cannon Research Institute, Florida Cancer Specialists, 34232 - Sarasota/US
  • 2 Department Of Medical Oncology, Nevada Cancer Research Foundation, 89106 - Las Vegas/US
  • 3 Department Of Medical Oncology, Associates in Oncology, 20850 - Rockville/US
  • 4 Division Of Arizona Center For Cancer Care, Pinnacle Oncology Hematology, 85258 - Scottsdale/US
  • 5 Oncology Center, Department Of Medical Oncology, Sint-Augustinus Hospital, 2610 - Antwerp/BE
  • 6 Seoul National University College Of Medicine, Department Of Internal Medicine, Seoul National University Bundang Hospital, 46-307 - Seongnam/KR
  • 7 Department Of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203 - Nashville/US
  • 8 Department Of Biostatistics, Merck KGaA, 64293 - Darmstadt/DE
  • 9 Immuno-oncology, EMD Serono, Inc., 01821 - Billerica/US
  • 10 National Institutes Of Health, Genitourinary Malignancies Branch, Center for Cancer Research-National Cancer Institute, 20892 - Bethesda/US


Abstract 2534


Avelumab* is a fully human IgG1 antibody that inhibits PD-L1. In a large phase 1b study (NCT01772004), avelumab showed preliminary safety and efficacy in a cohort of 44 patients (pts) with metastatic urothelial carcinoma (mUC) progressed after platinum-based chemotherapy or platinum ineligible. An additional cohort was enrolled to further characterise efficacy and safety of avelumab in mUC.


Eligible pts received avelumab 10 mg/kg (1h IV infusion) Q2W until confirmed progression, unacceptable toxicity, or withdrawal. Tumours were assessed every 6 wks (RECIST 1.1) and reviewed by an independent committee. Confirmed objective response rate (ORR) and progression-free survival (PFS) were evaluated. Adverse events (AEs) were graded by NCI-CTCAE v4.0.


As of Jan 18, 2016, 129 pts were treated with avelumab, including 113 (87.6%) with disease progression after platinum-based therapy and 9 (7.0%) who were platinum ineligible. Primary tumour sites were bladder (74 pts, 57.4%), urethra (23 pts, 17.8%), renal pelvis (22 pts, 17.1%), or ureter (8 pts, 6.2%). Median time from metastatic diagnosis was 10.7 mos. Pts had received a median of 2 prior lines (range, 0-6) for advanced disease. Median duration of treatment was 10.4 wks (range, 2-36). 78 pts (60.5%) had a treatment-related (TR) AE; most common (≥10%) were infusion-related reaction (29 pts [22.5%]) and fatigue (19 pts [14.7%]). 9 pts (7.0%) had grade 3-4 TRAEs, of which only fatigue (2 pts [1.6%]) occurred in >1 pt. There was 1 treatment-related death (pneumonitis). Among 109 pts with ≥4 mos follow-up, confirmed ORR was 16.5% (95% CI: 10.1, 24.8) with 3 complete responses and 15 partial responses; 17/18 ongoing (94.4%). 21 pts (19.3%) had stable disease. Median PFS was 6.1 wks (95% CI: 6.0, 8.3) and PFS rate at 12 wks was 35.6% (95% CI: 26.5, 44.7).


Avelumab showed promising efficacy with durable responses and a manageable safety profile in pts with mUC who were platinum ineligible or progressed after platinum chemotherapy, confirming previous findings. Enrolment of 200 pts is planned. PD-L1 expression analysis is ongoing, as is a randomised phase 3 trial in mUC. *Proposed INN.

Clinical trial identification


Legal entity responsible for the study



EMD Serono, Inc. and Merck KGaA


J. Ellerton: Research Funding: Merck. M. Gordon: Research Funding: Merck Serono. K-W. Lee: Research Funding: Merck Serono, AstraZeneca, Taiho, Roche, and Ono Pharmaceuticals. J. Infante: Consulting or Advisory Role and Research Funding: EMD Serono. M. Schlichting: Employment: Merck KGaA, Darmstadt, Germany. K. Chin: Employment and Research Funding: EMD Serono Stock or Other Ownership: Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings